On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter financial results during its earnings call. The full transcript is provided below.

This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.

Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1758586&tp_key=307852c58b

Summary

Verrica Pharmaceuticals Inc reported a total revenue of $5 million for Q1 2026, with U.S. Wycanth product revenue increasing by 25.4% compared to Q1 2025.

The company is advancing its global Phase 3 program for common warts, achieving over 50% enrollment in the first trial and planning to initiate a second trial by mid-2026.

Verrica is working on expanding the availability of WYCANT globally, with recent launches in Japan and plans to submit for approval in the EU.

The company introduced WycanthRx, a non-dispensing pharmacy, to improve access and fulfillment of prescriptions, which is seeing positive early adoption.

Verrica's net loss for Q1 2026 was $9.7 million, with cash reserves expected to fund operations into Q1 2027.

Management highlighted the potential of BP315 for basal cell carcinoma, emphasizing its strong Phase 2 results and ongoing market research to gauge reception.

Full Transcript

OPERATOR

Good day ladies and gentlemen and welcome to Verrica Pharmaceuticals Inc first quarter 2026 earnings conference call. At this time, all participants are in a listen only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSite Advisors. You may begin your conference.

Kevin Gardner (Moderator)

Thank you Operator. Hello everyone and welcome TO Verica Pharmaceuticals First Quarter 2026 Corporate Update Conference call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, David Zawitz, Chief Operating Officer and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward looking statements. These forward looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in. In such forward looking statements, please see Verica's SEC filings for important risk factors. Verica cautions you not to place undue reliance on forward looking statements and undertakes no duty or obligation to update any forward looking statements as a result of new information, future events or changes in expectations. In addition, during today's call, management will discuss certain non GAAP financial measures. These non GAAP financial measures are in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with gaap. There are a number of limitations related to the use of these non GAAP financial measures compared to their closest GAAP equivalents. The earnings release that the company issued today includes GAAP to non GAAP reconciliations for these measures and is also available on the Investor Relations section of Verica's website. I'll now turn the call over to Verica's President and CEO Jason Rieger.

Jason Rieger (President and Chief Executive Officer)

Thank you, Kevin. Good evening everyone and thank you for joining us on our first quarter 2026 corporate update call. I am pleased to report that in the first quarter we saw accelerating growth in market demand for WYCANTT, setting new records for dispensed applicator units during the quarter and in the month of March. This growth continued after the end of the quarter as we observed further increased demand in April. WYCANTT also achieved another significant milestone in February as our partner, Tory Pharmaceutical launched WYCANTT in Japan for patients with molluscum following their regulatory approval last year. Our hope is that Japan is only the beginning of our global expansion efforts for WYCANTT as we are actively working to expand the availability of WYCANTT into new markets around the world. While we grow the WYCANTT business, we're also advancing our product portfolio. As you may recall, in January we announced that the first patient had been dosed in our global Phase three program for the treatment of common warts, which represents a critical milestone in our strategy to expand into new indications. I'm proud to announce that we have achieved more than 50% of the currently targeted enrollment in the first phase 3 trial, also known as COV2, and have begun enrolling patients in the long term follow up study in this program. Our target is to initiate the second Phase 3 trial, known as CoV3 in this program by mid-2026. We also continue to advance our Phase 3 ready asset, BP315 for the treatment of basal cell carcinoma. As we've begun efforts to secure clinical supplies and select a CRO to support initiation of the Phase 3 program, BP 315 is garnering increasing attention within the dermatology community. Based on compelling proof of concept data from our Phase II program, I'll now provide a detailed update on our WYCANTP commercial business. In the first quarter of 2026 we reported total revenue of $5 million, including U.S. wycamp product revenue of $4.3 million which was up 25.4% over the first quarter of 2025. First quarter, U.S. wicamp dispensed applicator units increased to 15,302, growing 51.3% over the 1st quarter of 2025. On a sequential basis, U.S. wicanth revenue and dispensed applicator units increased 15.3% and and 12.1% respectively compared to the 4th quarter of 2025. As noted in our last call in March, while demand for WYCANTT in January was likely impacted by severe winter weather across the east coast, demand accelerated sharply in February and continued into March which saw the best monthly dispensed applicator unit total since the launch of wicant. As we have now seen preliminary results for April, I am pleased to note that April dispensed applicator units also increased from March's then record level and our team worked diligently every day to help more healthcare providers treat molluscum with what we believe to be is the best treatment available. Licamp as we've noted in prior quarters, as we continue to prioritize the ease of access for healthcare providers and their patients, we continue to make substantial investments in our copay assistance program which is impacted during the first few months of each year by the annual reset of insurance plan deductibles in January. To ensure the broadest access to WYCANT for healthcare providers, we launched WycanthRx, our non dispensing pharmacy, in the fourth quarter of 2025. WycanthRx simplifies the process for both the healthcare provider and patient by performing an initial benefit investig and then triaging to an in network dispensing pharmacy based upon the patient's unique healthcare coverage. Although ycamp Rx is still in the early stage of rollout, is being well received and in our view will help further drive demand and coverage for wicanth. We would again like to congratulate Tory Pharmaceutical, now a subsidiary of Shinogi, on their February commercial launch of WYCANTT in Japan for patients with molluscum. This milestone reflects the culmination of significant efforts by many team members from both companies. The launch of WYCANTT in Japan means that the commercial supply we provide to Tori has begun to offset Erica's portion of the clinical costs for the CommonWART program. As we announced in February. We also brought on board Chris Chapman as our new Chief Commercial Officer in the first quarter. Chris and his team are already doing an outstanding job in optimizing our resources to maximize the productivity of the WYCANT commercial efforts. Finally, as noted on our fourth quarter call, the Committee for Medicinal Products for Human Use of the European Medicines Agency provided positive feedback that supports the filing of a marketing authorization application for WYCANT as a treatment for Molescam. With no further phase 3 clinical trials required for product approval, we are actively progressing through the next steps for submission in the eu. The EU represents a substantial market opportunity for wycamp and we look forward to evaluating potential commercialization partnerships in this large and underserved region. With respect to our pipeline, the Commonwealth and basal cell carcinoma clinical programs include continue to move ahead, representing what we believe can be multi billion dollar opportunities. As I mentioned, in December 2025 we dosed the first patient in the first phase 3 trial. CoV2 evaluating Wycan for CommonWARTS, which continues to enroll patients. The second phase 3 trial in the CommonWART program, CoV3 with sites in both the United States and Japan, is targeted to be initiated by mid2026. If the Phase 3 program is successful, Wicanth could become the first therapy ever approved in the United States and Japan to treat common warts, a condition that impacts over 22 million people in the US alone. As a reminder, Verica and TORI will split the cost of the program 5050 with Tori funding the first $40 million of trial costs, representing approximately 90% of the current trial budget. We expect to repay our portion by offsetting future transfer payments, milestones and royalties relating to wicant sales in Japan. As a reminder, all of the efforts we are undertaking for the commercialization of wicant for molluscum lay the foundation for ultimate commercialization for the Commonwealth indication if approved, and there will be significant overlap in the clinicians treating both molluscum and commonwealts with the ability to access the same applicator through the same distribution channels. With respect to VP315 for basal cell carcinoma, our program continues to drive strong interest with clinicians and patients alike as potential alternative approach to the existing surgical and non surgical options. In our phase 2 study, treatment with VP315 demonstrated a 97% objective response rate and an 86% reduction in overall tumor size, with more than half of the treated lesions achieving complete histological resolution. We continue to share additional data from the ongoing analysis of the results from the Phase two at scientific conferences. As reported last week, we will formally be presenting at the 2026 Society for Investigative Dermatology, or SID, at their annual meeting in Chicago later this week and will be sharing additional data regarding the abscopal like observations from the phase 2 study. With a strong scientific foundation from our phase 2 results and regulatory engagement. We have also recently completed several market research activities to better understand how VP315 would be received by various stakeholders. This work supports broad potential utilization and acceptance across general dermatologists, medical oncologists and MOHS surgeons as well as office managers and payers. We also conducted market research to evaluate the patient perspective which indicated that a substantial majority of patients would elect to try VP315 before other existing therapeutic options regardless of whether they had previously been treated for skin cancer. While the best outcome for patients is to completely eliminate the tumor, which we have observed in many patients, in our phase 2 study overall tumor size was reduced on an average by 86%, which we view as clinically meaningful. This highlights the potential for VP315 to improve the patient experience by reducing the size and potential complexity of future procedures, even where surgical excision is ultimately required in totality. This market research reinforces our conviction and enthusiasm for the potential of BP315 to change the paradigm for treatment of basal cell carcinoma. We continue to actively assess a variety of funding opportunities for this program and have initiated clinical and CMC activities to proactively prepare for the commencement of the Phase 3 program. As previously noted, Verica has retained 100% global commercial rights to WYCANT for all approved and potential indications outside of Japan, as well as full global rights to VP315 for non metastatic skin cancers, including basal cell and squamous cell carcinoma. These programs represent a robust opportunity for potential partnership to create shareholder value and optimize global access to patients that can benefit most from these medicines. I'll now turn over the call to our Interim Chief Financial Officer John Kirby to review our first quarter 2026 financials.

John Kirby (Interim Chief Financial Officer)

Thanks Jason. I'll now take a few minutes to summarize our financial Results for the first quarter ended March 31, 2026. Total revenue for the first quarter of 2026 was $5 million, consisting of 4.3 million of of U.S. net WYCANT revenue and $0.7 million of license and collaboration revenue associated with our TORY partnership, compared to $3.4 million of U.S. net WYCANT revenue and $17,000 of license and collaboration revenue in the first quarter of 2025. Net Wycan revenue in the first quarter of 2026 reflects shipments to our distribution partners offset by standard gross to net adjustments, including actual or anticipated product returns off invoice discounts, distribution fees, rebates and co pay assistance program expenses. Gross product Margins for the first quarter of 2026 were 87.3% compared to gross product margins of 87.6% compared to for the prior year period. Cost of product revenue for the first quarter of 2026 was $0.5 million versus $0.4 million for the prior year period, consisting primarily of product costs related to the sale of Wycamp Research and Development expenses of $3.9 million in the first quarter of 2026 increased by $1.5 million when excluding the impact of stock based compensation compared to $2.3 million in the first quarter of 2025 due to increased spend on the Commonwealth Program. Selling General and administrative expenses of $10 million in the first quarter of 2026 increased by $1.3 million when excluding the impact of stock based compensation compared to the expense of $8.8 million in the first quarter of 2025, driven primarily by increased commercial spend related to the expansion of our sales force. GAAP net loss was $9.7 million or $0.45 per share for the first quarter of 2026 compared to a gap net loss of $9.7 million or $1.03 per share for the first quarter of 2025 on a non GAAP basis, which excludes stock based compensation, non cash interest expense and change in fair value of embedded derivatives. The first quarter of 2026 net loss was $8.8 million or $0.41 per share, compared to a net loss of $8.3 million or $0.88 per share for the first quarter of 2025. And finally, as of March 31, 2026, Verica had aggregate cash of $20.6 million, which is expected to fund operations into the first quarter of 2027. I'll now turn the call back over to Jason for closing remarks.

Jason Rieger (President and Chief Executive Officer)

Thanks John we are steadfastly advancing our efforts to establish Wicamp as the new standard of care for molluscum and and are seeing traction with our strongest quarter in dispensed applicator units since launch. We are also positioning our company to fully capture the significant opportunities which lie ahead for our advanced stage pipeline if these programs successfully complete their development and are approved. Based on our Phase two data, the feedback from the dermatology community and alignment with the FDA on the Phase 3 program design, we believe BP315 truly has the potential to fundamentally change the treatment paradigm of basal cell carcinoma. In addition, the opportunity to expand WYCANT label into commonwealts would open in a new addressable patient population for which there currently remains no FDA approved therapies. We believe each of these two opportunities represent significant potential upside for our company and for our shareholders and we are excited about the future for Verica and the potential impacts for patients. With that, we'd be happy to answer your questions.

OPERATOR

Operator thank you. And if you would like to ask a question, please press Star one on your keypad. To leave the queue at any time, press Star 2. Once again, that is Star N1 to ask a question. We'll take our first question from Stacy Ku with TD Cowan. Please go ahead. Your line is open.

Stacy Ku (Equity Analyst)

Hey there, thanks so much for taking your questions. Congratulations on the enrollment progress for your Commonwealth program and also on the quarter for Y camp. First consensus for the year seems about be around kind of the mid 20 million kind of range to the extent that you can comment, but what are your views given what seems to be very encouraging growing demand in April? That's the first question. And then second, I know this can be a little location specific, but are you expecting to see seasonality with Molescom this year? And what are you doing to ensure you can capture any type of increased rates in the summertime, would you also assume the WICAN Prescription Hub services to start driving adoption and improving fulfillment around that timeframe? So that's the second question. The third is to get an update on the progress of expanding the sales force in regions that you're seeing good wide camp adoption. So just help us understand what you're seeing in terms of the additional stepwise expansion and if we should expect any additional updates with the salesforce to help us understand the progress when it comes to wide camp adoption. And also maybe potentially why can't access and then last, as you think about BP315, just maybe help us understand as you think about Phase three where you expect the product to be positioned in the BCC treatment paradigm, what type of patient profile for BCC would opt for a product like this? Thanks so much.

Jason Rieger (President and Chief Executive Officer)

Thank you Stacy. I appreciate it. I think I made good notes on all of your questions. I'll do my best, but I'm sure you'll correct me if I miss any Starting with the consensus, we're very excited about the progress we're making. We saw a good ending to the Q1 solid performance so far in April and we're excited about the prospects of the year. It's premature to give guidance at this point, so we're going to leave that number alone. But what we're seeing right now, it gives us confidence on the growth that we're seeing and the performance over the course of the year. But with regards to seasonality, depending on where you look and who you ask, there's all kinds of comments on when the seasonality would be. But overall I think there's general consensus to see growth as you enter the spring and summertime, and I think that's where we are right now and that could be contributing to some of the growth we're seeing. But a lot of it also comes down to the execution on the commercial side and the general adoption of WICAM that we're starting to see. And I'll let Chris comment a little more on your questions regarding the salesforce and the sales focus in a moment. But one of those tools that's certainly going to help and we're starting to see some adoption is the WycanthRx in our hub to help support the routing of scripts and importantly, fulfillment of scripts, facilitating it for the clinicians and the patients to make that access as easy as possible. I'll let Chris comment a few minutes on your question on the commercial side, and I'll round out the Wicam on 315.

Chris Chapman (Chief Commercial Officer)

Thank you, Stacy, for the question. And you know, as Jason mentioned in the opening, I joined in March and I've been very pleased with what I found in the organization. But there are areas for optimization. You mentioned the field force. Currently we are deployed and our territories do capture about 85% of the TAM. However, there are areas that we can optimize reach and frequency and we are going through kind of stem to stern reach and frequency exercise. We will be staffing to about approximately 50 representatives. There are numerous markets that could use additional manpower. And I think you're seeing in the momentum that we're building slight tweaks to our deployment and our execution are yielding some momentum. And I remain cautiously optimistic on that. But again, we're totally reevaluating our current targeting to optimize that reach and frequency, which again gives us the opportunity to optimize 85% that we're already deployed against.

Jason Rieger (President and Chief Executive Officer)

Thanks, Chris. And I'll let Noah comment a little bit on your question on VP315.

Noah Rosenberg (Chief Medical Officer)

In terms of our Phase 3 program, our initial approach is to target patients with low risk basal cell carcinoma that is nodular and superficial, and to target a similar population to what we saw in phase two. Those would be primary tumors. I think broadly beyond Phase three, I think it's important to also recognize that we see this as potentially long term a neoadjuvant approach for complex and difficult to treat tumors. And very excited about the obscopal data, which has some implication potentially for patients who often present with multiple lesions at initial presentation.

Jason Rieger (President and Chief Executive Officer)

Thanks, Noah, and thanks, Chris. To round that out, one of the feedback that we've generally seen from patients we've asked about their perspective on this treatment is those who are naive to ever having had treatment with basal cell or those who have had multiple basal cell experiences before, seem to be very receptive towards the potential of BP315 as a method to as their first line of therapy to try and see if they can reduce the size or perhaps eliminate the lesion. And that bodes well both for them as well as if you proceed down to Mohs or other procedures where that lesion is smaller and that surgical procedure would be simpler in terms of complication, potential scarring, side effects, et cetera.

Stacy Ku (Equity Analyst)

Super helpful, thank you as always.

Georgia (for Dennis Ding)

Thank you. We will move next with Dennis Dink with Jeffries, please. Go ahead. Hello, this is Georgia bank on the line for Dennis Ding. Thank you for taking your questions and congratulations on the quarter. I guess another question on the 315 program and on the SID data. I guess showing reductions in untreated lesions consistent with the potential upscopal effect. How are you thinking about validating that signal going forward? And how should we think about the opportunity of that market where patients might have multiple lesions versus just a single? And what would that look like? And then a follow up on the wicanth Rx pharmacy model and how it's performing today and what proportion of scripts are routed through that pharmacy. And what are you seeing in terms of differences in prescription to, you know, treatment conversions or reimbursement success rates and so on.

Noah Rosenberg (Chief Medical Officer)

So it's Noah here, I think in terms of the abscopal effect and the overall implications, the patient population, I think many patients present initially with multiple lesions. Often patients, especially those who've already had procedures, want a surgical alternative. So again, we see this as complementary to surgery, but in some cases patients may not want that surgery and in some cases they've got more than one lesion. So we believe that this data, while early and exploratory, is extremely encouraging in terms of validating that data. We plan, as we've mentioned, 2 larger studies, 100 patients each in phase 3. And we'll be able to explore and look at larger populations and look at that Episcopal effect. I think it's important to note that regardless of whether the patients were contralateral or they were nearby in terms of the lesions, we still saw effects broadly. And I think that was extremely encouraging and we're very excited to embark on that data.

Georgia (for Dennis Ding)

This is David Zawitz speaking on wecanthr X. THER X performance has been good in the early few months since we launched it. It's an option that we provide to the prescribers who are looking to write the product. It's not mandatory. They can choose to write it if they are looking for the additional help with benefits investigations and with potentially processing prior auths if they're required. And so far we've been improving the program throughout the quarter since the launch and it's been going well. We're not going to comment right now on sort of percentage of our total business that's running through that, but the adoption is growing and it's going to be proving to be a useful option for prescribers who are looking to use it. Understood.

OPERATOR

Thank you. Thank you. We will move next with Serge Bellinger with Needham company. Please go ahead. Your line is open.

Georgia (for Dennis Ding)

Good afternoon. Thanks for taking the questions. First one, I guess just on the 1Q performance, just trying to understand the variability from quarter to quarter in your gross to nets to reconcile the difference between the applicator unit growth and sales number. And then secondly, can you maybe just talk about competitors molluscum product that's currently in the market, whether it's been a headwind for why can't or maybe it's there's been a tailwind due to the additional voice in the market promoting molluscum. Thanks, George.

Chris Chapman (Chief Commercial Officer)

Thanks for the question. It's Chris Chapman. And you know, I think the variation certainly that you see between Q4 and Q1, you know, Q4, Q4 historically is the most valuable month for manufacturers. You know, most of the patients have cleared their deductibles and people are refilling their prescriptions. Q1, you do have the deductible reset. So I think we saw a little bit of that. But as I mentioned in my prior comments, you know, I'm really encouraged at the momentum that we saw coming out of Q1 into the first month of Q2. And there, there are a couple of reasons and they all relate to the questions that have been asked here. One is wycanthrx, which provides a useful option for those physicians who need some additional support. The other, as you mentioned, is having additional share of voice. Having a second competitor in the market driving recognition and choosing to treat molluscum is a huge opportunity that we certainly are taking advantage of. The third, as I mentioned, being new to Verica, is the opportunity to do some basic optimization on reach and frequency on your targets. And so I think those three areas. But again, I would anticipate you're continually going to see a synergistic effect of share of voice in the marketplace as well as those additional commercial levers that we're pulling. Expect to see more guidance as we get into Q3 and Q4. But right now, as I mentioned, cautiously optimistic, but impressed with the early results that we see. Thanks, Chris.

Jason Rieger (President and Chief Executive Officer)

And I said to follow up, what we've seen is this is a market dominated by a watch and wait mentality. And now that we have a clinical, a viable option for treatment, and we believe WCANCE really addresses the unmet need by one to two treatments on average for most patients to get to a resolution that they're happy with in terms of their disease, we believe that will continue adoption and convert those from watching to actually getting treated and awareness of the disease, and that there's therapies out there bodes well for our program. Thank you.

OPERATOR

Thank you. We will move next with Ram Silveradju with HC Wainwright. Please go ahead.

Ram Silveradju (Equity Analyst)

Thanks so much for taking our questions just with respect to Europe, could you maybe elaborate on how you anticipate reference pricing to shake out as and when the product ultimately becomes eligible for market entry? And also if you could give us a sense of post approval, what the country by country cadence might be, which countries are most likely to be first in line for wycan's introduction? Thank you. Thanks, Rob. I appreciate that you. We're still in the early stages of our Europe planning and strategy works. We have ongoing activities with regards to understanding pricing and pricing options and what reimbursement might look like there. We've explored that in a number of countries and we'll continue to share that information as it's ripe to do so. In terms of countries, we're planning to have broad access across the eu. Obviously there are some strategies on which countries may come first in that I would say we will probably be more consistent with traditional European rollouts, but we're going to evaluate that based on the feedback on a country by country basis and the addressable population as well as the pricing that may differentiate across those countries. But that work is ongoing in parallel to our work to complete the regulatory submission activities. Can you also just briefly comment on any underlying emergent trends among both unique prescribers and repeat prescribers of Wycans that you're seeing in the most recent data?

Chris Chapman (Chief Commercial Officer)

Yeah, I can speak to that. And we're seeing what you would expect to see. The dermatologists dominate the early adoption and you see that across classes. You also see it across competitors in this space. And as you would imagine, you're also seeing repeat prescribing in those earliest adopters. And as we continue to expand that prescriber pool, you see more and more pediatricians coming in. So clearly those are the two largest segments. But as you might imagine, dermatologists were the early adopters in molluscum in the selection to both diagnose and to treat and to retreat additional patients.

Ram Silveradju (Equity Analyst)

Thank you.

OPERATOR

Thank you. We will move next with Kemp Dolliver with Brookline Capital Markets. Please go ahead.

Chris Chapman (Chief Commercial Officer)

Great, thank you. What do you see as the gating factors behind demand? Now, if you look back over the history of the launch, there was reimbursement, there was compounded product in a lot of offices on the market. You know, what do you see as the key things you need to overcome at this stage? Assuming that those. The first couple things I mentioned have been resolved? Yeah, I don't know if I would, if I would call access resolve. Certainly we've achieved a steady state and a target access now we have the need to pull it through, you know, into the children accounts of the pbm. So there are still geographic opportunities for us to pull it through. But I think the real gating factor is what you kind of hear a theme in my answers here. It's appropriate targeting and segmentation. You know, of course we need to get that early adoption and we need to get trial. But as you get into the pediatric segment, as Jason mentioned, you know, the biggest competitor is watchful waiting. And it's not that molluscum is not seen. It's with the prior lack of approved, FDA approved medications, it wasn't treated. And so now the gating factor to us is to drive trial wycanth works. And when we see physicians trial it, they rewrite it. So for us, it's continuing to grow those prescribers concentrically out from the early adopters, from those deciles, tens, nines, eights, getting down into those lower decile physicians, which will take us in more into that pediatric segment. So that becomes the real unique opportunity here in the next three to four quarters.

Kemp Dolliver (Equity Analyst)

Kevin, add to that. Oh, go ahead, please. I was just going to say follow up on that last point. Have you looked at whether there's a correlation between seniority of physician and willingness to trial? When you mean seniority, can you. What do you mean by that? Age. I'm sorry? Age. Oh, interesting.

Chris Chapman (Chief Commercial Officer)

Because in medical schools they used to teach them not to worry about it when you look at the senior physicians, because there were no options. But yeah, not necessarily. But I will tell you this, where we do see some differential is your physician extenders, those on the front lines, in the trenches, your nurse practitioners, your PAs, they are very, very open to treating. And so I guess in a way, you know, you might be able to extrapolate that to age, but I think that's more of a relevant dynamic. Are the nurse extenders or physician extenders? But yeah, I really don't see it as age. But I will say, you know, dermatology as a whole is very familiar with Catheridin primary care. Less so. So I think the trial that we've seen early is to be expected. The adoption that we're now seeing in dermatology is to be expected and the opportunity remains as we expand out into pediatricians.

Jason Rieger (President and Chief Executive Officer)

And Kim, to follow up, two more points to address some of your comments. You know, we've spent the last year working on distribution and access and availability of the product for clinicians who want to treat. And this quarter you just, we just announced in our release which we crossed over 100,000 applicator that have been dispensed since launch. One of the things as Chris refers to the early adopters versus starting to expand beyond that you start to get a critical amount of adoption and utilization outside post clinical trials and that gives the later adopters and those who like to watch and take their time data to see that the safety profile is consistent with what we saw in the clinical studies, the efficacy is being consistent with what was seen. And so both of those things really bode well for those next wave of adopters to start to come aboard. And we've worked very hard to make it the access to be easy with our copay support, our medical education and just awareness of the product for treatment of Beloscope. Thank you.

OPERATOR

We will move next with Dev Prasad with Lucid Capital Markets. Please go ahead.

Dev Prasad (Equity Analyst)

Thank you for taking our caution and congrats on the progress. I have a couple one following up the last one, I'm not sure if you answered it or not, but are you seeing wycant growth primarily from new prescriber entering this launch curve or from higher utilization from existing high volume account and second is what are the next gating steps for EU submission and potential launch? Thank you.

Chris Chapman (Chief Commercial Officer)

Thanks for the question. And we're really seeing both those prescribers who trialed early are continuing to prescribe, but we are seeing a much quicker acceleration as we get into that early majority segment of the physician cohort. So I think we're going to continue we have to drive both. Of course when you do have a competitor come out, those earliest adopters are going to trial that brand which is a good thing. But we are seeing continued growth in both segments and we'll continue to focus on the highest deciles 10 through 8 to make sure that we have that secure as we continue to expand into the rest of the market.

Jason Rieger (President and Chief Executive Officer)

With regards to Europe, there's obviously a number of steps that you have to go through. We have received our initial scientific advice regarding the general scope of what a submission would look like for approval. Now we need to go through the process, for example securing pediatric investigation waivers, repertoire assignment, et cetera. And so we're going through that process now. And as indicated previously, Verica has retained global rights to white camp outside of the United outside the United States. Except for Japan which is controlled by Tory, we have those rights and you know we'll continue to explore that for a European partner to support both the commercialization process to address some of the earlier questions as well Great. Thank you. Yep.

OPERATOR

Thank you. And at this time, there are no further questions in queue. I will now turn the meeting back to CEO Jason Rieger for closing comments.

Jason Rieger (President and Chief Executive Officer)

Thank you, operator. And thank you, everyone, for your time and attention. I'd like to thank you for joining us this evening, and we look forward to providing more updates on our progress throughout 2026. Have a nice evening.

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice.